JNJ (Johnson & Johnson) Total Stockholders Equity: $84,971 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JNJ Johnson & Johnson JNJ
83 GF Score
Price $263.09
GF Value $192.35
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Total Stockholders Equity?

Johnson & Johnson JNJ +1.05% 83 Total Stockholders Equity is $84,971 Mil as of Jun. 2026. GuruFocus rates JNJ with a GF Score™ of 83/100 and a GF Value™ of $192.35 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Johnson & Johnson's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $84,971 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Johnson & Johnson's Book Value per Share for the quarter that ended in Jun. 2026 was $35.28. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Johnson & Johnson's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.58.


Johnson & Johnson  (NYSE:JNJ) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Johnson & Johnson's Book Value per Share for the quarter that ended in Jun. 2026 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Johnson & Johnson's Debt-to-Equity for the quarter that ended in Jun. 2026 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Johnson & Johnson Total Stockholders Equity Related Terms


Johnson & Johnson Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Total Stockholders Equity Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74,023.00 76,804.00 68,774.00 71,490.00 81,544.00

Johnson & Johnson Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78,473.00 79,277.00 81,544.00 81,186.00 84,971.00
JNJ
83GF Score
Johnson & Johnson JNJ
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $84,971 Mil mean?
Johnson & Johnson (JNJ) has a Total Stockholders Equity of $84,971 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Johnson & Johnson and its competitors.
Is Johnson & Johnson's Total Stockholders Equity too high?
Johnson & Johnson's current Total Stockholders Equity is $84,971 Mil. Overall, Johnson & Johnson has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Total Stockholders Equity compare to ABBV and MRK?
Johnson & Johnson's Total Stockholders Equity of $84,971 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Johnson & Johnson and its competitors. Johnson & Johnson's current Total Stockholders Equity is $84,971 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is $192.35, compared to a current price of $263.09 — trading 36.8% above its estimated fair value. The current Total Stockholders Equity is $84,971 Mil. Johnson & Johnson's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Johnson & Johnson (JNJ), the current Total Stockholders Equity is $84,971 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson & Johnson (JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of $263.09 is trading 36.8% above its estimated GF Value™ of $192.35. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for JNJ:

  • Total Stockholders Equity: $84,971 Mil
  • GF Value™: $192.35 vs. price of $263.09 (36.8% above fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
83GF Score

Get the complete analysis for JNJ

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$263.09
Price
$192.35
GF Value